Citation Impact
Citing Papers
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Sirtuins as regulators of metabolism and healthspan
2012 Standout
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
2015
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
2007 Standout
Short-term and long-term effects of caesarean section on the health of women and children
2018 Standout
Microbial tryptophan catabolites in health and disease
2018 Standout
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes
2008 Standout
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
2014 Standout
Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity
2016
Renal and Extrarenal Effects of Gum Arabic (Acacia Senegal) - What Can be Learned from Animal Experiments?
2013 Standout
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
2012
Unique binding mode of Evogliptin with human dipeptidyl peptidase IV
2017
Identification of Novel Human Dipeptidyl Peptidase-IV Inhibitors of Natural Origin (Part I): Virtual Screening and Activity Assays
2012
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
Current understanding of the human microbiome
2018 Standout
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
2009
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter
2010
AKT/PKB Signaling: Navigating the Network
2017 Standout
METABOLIC ACTIVATION OF FLUOROPYRROLIDINE DIPEPTIDYL PEPTIDASE-IV INHIBITORS BY RAT LIVER MICROSOMES
2004
Type 2 diabetes mellitus
2015 Standout
The immunopathology of sepsis and potential therapeutic targets
2017 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Asymmetric Synthesis of 3‐Amino‐δ‐lactams and Benzo[a]quinolizidines by Catalytic Cyclization Reactions Involving Azlactones
2009
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Stearoyl-CoA Desaturase 2 Is Required for Peroxisome Proliferator-activated Receptor γ Expression and Adipogenesis in Cultured 3T3-L1 Cells
2007
PPARγ in human and mouse physiology
2007
Insulin signalling mechanisms for triacylglycerol storage
2013
Functional Roles of the IgM Fc Receptor in the Immune System
2019 StandoutNobel
Lipotoxicity in renal proximal tubular cells: Relationship between endoplasmic reticulum stress and oxidative stress pathways
2010
Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis
2017
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects – A review
2015 Standout
AIMing at Metabolic Syndrome - Towards the Development of Novel Therapies for Metabolic Diseases via Apoptosis Inhibitor of Macrophage (AIM) -
2011
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Synthetic approaches to the 2011 new drugs
2013
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
2013
Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
2014
The Controversial Role of Human Gut Lachnospiraceae
2020 Standout
Complete Field Guide to Asymmetric BINOL-Phosphate Derived Brønsted Acid and Metal Catalysis: History and Classification by Mode of Activation; Brønsted Acidity, Hydrogen Bonding, Ion Pairing, and Metal Phosphates
2014 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Pomegranate husk extract, punicalagin and ellagic acid inhibit fatty acid synthase and adipogenesis of 3T3-L1 adipocyte
2013
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
2013
Works of Moh Tadayyon being referenced
Expression and functional activity of PPARγ in pancreatic β cells
2004
Inhibition of fatty acid synthase prevents preadipocyte differentiation
2005
(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
2008
Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
2008
Mono‐unsaturated fatty acids protect against β‐cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure
2004
8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
2007
Insulin sensitisation in the treatment of Type 2 diabetes
2003